MDNAF Medicenna Therapeutics Corp. IFRS
Pharmaceutical Preparations · OTC · SEC CIK 1807983 · Reporting currency CAD · Fiscal year ends 03/31
Financial factors as of 2023-03-31 (FY2023), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY—
TTM net income YoY55.5%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-39.9%
ROA-33.5%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets19.1%
Debt / equity0.00x
Current ratio9.57x
Interest coverage—
Cash quality & payout
Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: CAD | FY2023*2023-03-31 | FY2022*2022-03-31 | FY2021*2021-03-31 | FY2020*2020-03-31 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | — | — | — | — |
| R&D expense | 9.30M | 14.72M | 10.87M | 5.87M |
| SG&A expense | 7.00M | 7.76M | 6.53M | 2.38M |
| Pretax income | -10.05M | -22.58M | -17.29M | -8.28M |
| Income tax | 0 | 0 | 0 | 0 |
| Net income | -10.05M | -22.58M | -17.29M | -8.28M |
| EPS (basic) | -0.16 | -0.42 | -0.35 | -0.26 |
| EPS (diluted) | — | — | -0.35 | -0.26 |
| Balance sheet | ||||
| Cash & equivalents | 33.60M | 20.54M | 30.38M | 22.70M |
| Current assets | 36.38M | 23.39M | 42.15M | 37.85M |
| Intangibles | 61,000 | 65,000 | 71,000 | 76,000 |
| Total assets | 36.45M | 23.46M | 42.25M | 38.00M |
| Current liabilities | 3.80M | 2.62M | 4.11M | 1.81M |
| Total liabilities | 6.96M | 2.62M | 4.11M | 1.85M |
| Shareholders' equity | 29.49M | 20.84M | 38.15M | 36.15M |
| Shares outstanding | 69.64M | 55.65M | 53.55M | 46.80M |
| Cash flow statement | ||||
| Operating cash flow | — | -23.58M | -15.31M | -5.42M |
| Investing cash flow | — | 10.05M | 5.01M | -15.00M |
| Financing cash flow | — | 3.88M | 18.26M | 40.74M |
| Stock-based compensation | — | 1.42M | 1.01M | 1.12M |
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company does not report gross profit in XBRL.
· Amounts are in the company's reporting currency, CAD, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.